@article{424b3658adc74cecacdc30244b2a2161,
title = "Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates",
abstract = "The role of Achromobacterspecies in lung disease remains unclear. The aim of this study was to characterize Achromobacterisolated from persons with cystic fibrosis and from other clinical samples. Whole genome sequences from 101 Achromobacter isolates were determined (81 from patients with cystic fibrosis and 20 from other patients) and analysed. Taxonomic analysis showed nine species including two putative novel species. Thirty-five novel sequence types were present. The most active agent was co-trimoxazole followed by imipenem, but Minimal Inhibitory Concentrations (MICs) were high. Acquired antibiotic resistance genes were rare. Their presence did not correlate with minimal inhibitory concentrations suggesting that other mechanisms are involved. Genes for proposed virulence factors were present in only some isolates. Two putative novel species were identified. The putative virulence properties of Achromobacter involved in infections are variable. Despite the high MICs, acquired resistance genes are uncommon.",
keywords = "Achromobacter, antibiotic resistance, cystic fibrosis, taxonomy, virulence",
author = "Fluit, \{Ad C.\} and Bayjanov, \{Jumamurat R.\} and Aguilar, \{Mar{\'i}a D{\'i}ez\} and Barry Benaissa-Trou and Tunney, \{Michael M.\} and \{Van Westreenen\}, Mireille and Meis, \{Jacques F.\} and Elborn, \{J. Stuart\} and Rafael Cant{\'o}n and Ekkelenkamp, \{Miquel B.\}",
note = "Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number [115721-2], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. Spanish CF isolates were recovered from projects supported by Instituto de Salud Carlos III of Spain (grants PI12/00743 and PI15/00466) and cofinanced by the European Development Regional Fund (A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015). MD-A was partially supported by Fundaci{\'o}n Francisco Soria Melguizo (Madrid, Spain). Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number [115721-2], resources of which are composed of financial contribution from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. Spanish CF isolates were recovered from projects supported by Instituto de Salud Carlos III of Spain (grants PI12/00743 and PI15/00466) and cofinanced by the European Development Regional Fund (A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015). MD-A was partially supported by Fundaci{\'o}n Francisco Soria Melguizo (Madrid, Spain). Publisher Copyright: {\textcopyright} 2022 The Author(s).",
year = "2022",
month = jun,
doi = "10.31083/j.fbs1402009",
language = "English",
volume = "14",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "IMR Press Limited",
number = "2",
}